Table 2.
Long-term follow-up of biologicals in patients with therapy-refractory UP.
| Study | Number of patients with refractory UP | Biological | Long-term remission | Median follow-up (months) |
|---|---|---|---|---|
| Bouguen et al.24 | n = 13 | Anti-TNF (infliximab) | 69% (9/13) | 17 |
| Pineton De Chambrun et al.21 | n = 104 | Anti-TNF (infliximab, adalimumab, golimumab) | 64% (67/104) | 24 |
| This study | n = 26 | Anti-TNF (infliximab, adalimumab, golimumab) | 50% (13/26) | 21 |
| This study | n = 15 | Vedolizumab | 67% (10/15) | 11 |
anti-TNF: anti-tumour necrosis factor; UP, ulcerative proctitis.